Trial · NCT02763215
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of Non-ceruloplasmin-bound Copper (NCC) Or Reached A Reduction Of ≥ 25% In NCC During 6 Months Of Treatment | Baseline through Month 6 | To achieve a normalized NCC concentration, participants must have had 2 consecutive measures within (or below) the normal concentration range (0.8 to 2.3 micromolar \[μM\]). Two consecutive measurements required that the measurements occurred on separate dates and were assigned to 2 different visits. Non-ceruloplasmin-bound copper was calculated by subtracting the amount of copper bound to the ceruloplasmin from the total plasma copper concentration. |
| Secondary | Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of NCC Or Reached A Reduction Of ≥ 25% In NCC Through Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | To achieve a normalized NCC concentration, participants must have 2 consecutive measures within (or below) the normal range (0.8 to 2.3 μM). Two consecutive measurements required that the measurements occurred on separate dates and were assigned to 2 different visits. Non-ceruloplasmin-bound copper was calculated by subtracting the amount of copper bound to the ceruloplasmin from the total plasma copper concentration. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In NCC Concentrations At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | Evaluation of NCC concentrations over time are reported as micromoles/liter (μmol/L). Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Time To Normalization Of NCC If Above The Reference Range At The Time Of Enrollment | Baseline, up to 24 months | The time to normalization of NCC was measured by Kaplan-Meier analysis. |
| Secondary | Change From Baseline In Exchangeable Copper At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | The change in exchangeable copper was evaluated over time and is reported as nanograms/milliliter (ng/mL). Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In Copper Plasma Ultrafiltrate At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | Change in copper plasma ultrafiltrate was measured over time and is reported as ng/mL. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In Plasma Total Copper Used To Calculate NCC At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | Plasma total copper was measured over time and is reported as ng/mL. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In Serum Total Ceruloplasmin (Nephelometry) Used To Calculate NCC At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | The total serum (nephelometry) was measured over time and is reported as milligrams (mg)/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In 24-Hour Urinary Copper At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | Evaluation of 24-hour urinary copper over time is reported as micrograms (μg)/day. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In Plasma Total Molybdenum At Month 6 And Month 24 | Baseline, Month 6, Month 24 | The plasma total molybdenum was measured over time and is reported in ng/mL. |
| Secondary | Change From Baseline In Molybdenum Plasma Ultrafiltrate At Month 6 And Month 24 | Baseline, Month 6, Month 24 | The molybdenum plasma ultrafiltrate was measured over time and is reported as ng/mL. |
| Secondary | Change From Baseline In 24-Hour Urinary Molybdenum At Month 6 And Month 24 | Baseline, Month 6, Month 24 | Evaluation of 24-hour urinary molybdenum over time is reported as μg/day. |
| Secondary | Change From Baseline In Hepatic Laboratory Measures For Alanine Aminotransferase (ALT) At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | The ALT levels were measured over time and are reported as units (U)/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In Hepatic Laboratory Measures For Aspartate Aminotransferase (AST) At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | The AST levels were measured over time and are reported as U/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In Hepatic Laboratory Measures For Bilirubin At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | Bilirubin was measured over time and is reported as μmol/L. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In Hepatic Laboratory Measures For International Normalized Ratio (INR) At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | The INR was measured over time. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | Change From Baseline In Clinical Global Impression (CGI) Scale Item 1 (Severity Of Illness) At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | The CGI scale item 1 (severity of illness) rating scale is a commonly used measure of symptom severity, treatment response, and the efficacy of treatments in treatment studies of participants with mental disorders. It uses the Clinical Global Impression - Severity Scale (CGI-S), a 7-point scale that requires the Investigator to rate the severity of the participant's illness at the time of assessment, relative to the Investigator's past experience with participants who had the same diagnosis. Considering total clinical experience, a participant was assessed on severity of illness at the time of rating as: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. A decrease in score indicates improvement in disease severity. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
| Secondary | CGI Scale Item 2 (Global Improvement) At Month 6, Month 24, And Last Assessment | Baseline through Last Assessment (ranging from 1 to 24 months) | The CGI scale item 2 (global improvement) is a rating scale commonly used measure of symptom severity, treatment response, and the efficacy of treatments in treatment studies of participants with mental disorders. It uses the Clinical Global Impression - Improvement Scale (CGI-I), a 7-point scale that requires the Investigator to assess how much the participant's illness has improved or worsened relative to the Baseline state at the beginning of the study and rate as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. A decrease in score indicates improvement in disease severity. Last Assessment was the last available post-baseline result for each participant (ranging from 1 to 24 months). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02763215/registered